Cancer and multiple sclerosis : 2023 recommendations from the French Multiple Sclerosis Society
BACKGROUND: Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms of cancer risk.
OBJECTIVE: To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS).
METHODS: The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal.
RESULTS: Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations.
CONCLUSION: These recommendations propose a strategic approach to managing cancer risk in PwMS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Multiple sclerosis (Houndmills, Basingstoke, England) - (2024) vom: 15. Feb., Seite 13524585231223880 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Revised 15.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1177/13524585231223880 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368479714 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368479714 | ||
| 003 | DE-627 | ||
| 005 | 20240215232223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240215s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/13524585231223880 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM368479714 | ||
| 035 | |a (NLM)38357870 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Collongues, Nicolas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer and multiple sclerosis |b 2023 recommendations from the French Multiple Sclerosis Society |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a BACKGROUND: Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms of cancer risk | ||
| 520 | |a OBJECTIVE: To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS) | ||
| 520 | |a METHODS: The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal | ||
| 520 | |a RESULTS: Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations | ||
| 520 | |a CONCLUSION: These recommendations propose a strategic approach to managing cancer risk in PwMS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a checkpoint inhibitors | |
| 650 | 4 | |a disease-modifying treatments | |
| 650 | 4 | |a immunotherapy | |
| 700 | 1 | |a Durand-Dubief, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Lebrun-Frenay, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Audoin, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Ayrignac, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Bensa, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Bigaut, Kévin |e verfasserin |4 aut | |
| 700 | 1 | |a Bourre, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Carra-Dallière, Clarisse |e verfasserin |4 aut | |
| 700 | 1 | |a Ciron, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Defer, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Kwiatkowski, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Leray, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Maillart, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Marignier, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Mathey, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Morel, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Thouvenot, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Zéphir, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Boucher, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Boutière, Clémence |e verfasserin |4 aut | |
| 700 | 1 | |a Branger, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Da Silva, Angélique |e verfasserin |4 aut | |
| 700 | 1 | |a Demortière, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Guillaume, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Hebant, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Januel, Edouard |e verfasserin |4 aut | |
| 700 | 1 | |a Kerbrat, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Manchon, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Moisset, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Montcuquet, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Pierret, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Pique, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Poupart, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Prunis, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitt, Perrine |e verfasserin |4 aut | |
| 700 | 1 | |a Androdias, Géraldine |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Mikael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis (Houndmills, Basingstoke, England) |d 1997 |g (2024) vom: 15. Feb., Seite 13524585231223880 |w (DE-627)NLM09012992X |x 1477-0970 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:02 |g pages:13524585231223880 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/13524585231223880 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 02 |h 13524585231223880 | ||